United States - English - NLM (National Library of Medicine)

bluepoint laboratories - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia,as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3) ]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3) ]. schizophrenia •  

United States - English - NLM (National Library of Medicine)

lupin limited - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.2)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.2)]. ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. the efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatien

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 80 mg - ziprasidone hydrochloride capsule is an atypical antipsychotic. in choosing among treatments, prescribers should be aware of the capacity of ziprasidone hydrochloride capsule to prolong the qt interval and may consider the use of other drugs first (5.2) ziprasidone hydrochloride capsule is indicated as an oral formulation for the treatment of schizophrenia. (1.1) adults: efficacy was established in 4 to 6 week trials and one maintenance trial in adult patients with schizophrenia  (14.1) because of ziprasidone's dose-related prolongation of the qt interval and the known association of fatal arrhythmias with qt prolongation by some other drugs, ziprasidone is contraindicated: - in patients with a known history of qt prolongation (including congenital long qt syndrome) - in patients with recent acute myocardial infarction - in patients with uncompensated heart failure pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the qt interval have not been performed. an additive eff

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 90.6 mg (equivalent: ziprasidone, qty 80 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; gelatin; pregelatinised maize starch; lactose monohydrate; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 67.95 mg (equivalent: ziprasidone, qty 60 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; lactose monohydrate; titanium dioxide; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 45.3 mg (equivalent: ziprasidone, qty 40 mg) - capsule, hard - excipient ingredients: magnesium stearate; indigo carmine; titanium dioxide; lactose monohydrate; pregelatinised maize starch; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 22.65 mg (equivalent: ziprasidone, qty 20 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; indigo carmine; gelatin; lactose monohydrate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone capsules usp are indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)]. schizophrenia •ziprasidone capsules usp are indicated for th

United States - English - NLM (National Library of Medicine)

unit dose services - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.2)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.2)]. ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. the efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatien

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 90.6 mg - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; lactose monohydrate; gelatin; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.